Member Info for AquaeSulis01

I am currently trying to track warrants issued via allocation; does anyone know which placing resulted in warrants over 30,773,543 New Ordinary Shares at a price of 0.33 pence per share being exercised please?

Don, we have already been informed that "The RAB drill holes will be drilled on profiles across the three target areas in order to provide enhanced information of the subsurface shape and orientation of the ultramafic rock bodies being targeted and allowing for the optimisation of a planned follow-on diamond drill programme", so exploratory.

Also this is Katora Gold's show and they initiated today's RNS.

Finally, announcing that the drilling was underway end Dec is significant bearing in mind the Molopo Farm Christmas break appears to have extended into the second week of January

We planned to walk across the road, we have walked across the road AND DID IT TO TIME COST AND SCHEDULE WITH THE RISK OF BAD WEATHER NOT SO FAR MATERIALISING.

Now re-start end Dec is what I call a Christmas break.

The important thing is that actuals have beaten analyst predictions. From 24th Sep; Aynsley Lammin, analyst at Canaccord Genuity, said: "Clearly the balance sheet is in much better shape post the equity raise, with net cash at the end of August, and management is now implementing its new strategy. While the full-year underlying operating loss looks set to be a bit lower than we currently expect - probably around £80m versus the £90m we currently forecast - the second half is expected to remain loss making.

That's some Christmas break they have in Botswana.

867,859,942 shares on 30th November when PJ held 61500000 shares (7.09%). Shares now in issue are 1,004,685,868 which dilutes PJ's holding to 6.12% unless he has also exercised warrants.

Wool you also answered your own question 're still profitable with additio nal staff as the extract you quoted included the words "stronger team" so all good??

Whilst I believe it unlikely the Croda launch is anything to do with skinbio, this link does illustrate the future potential of a science backed quality product such as cleanbiotix, and hence future add on value to axisbiotix and skinbiotix once it is launched

https://www.hyperbiotics.com/blogs/recent-articles/our-top-5-favorite-microbe-friendly-household-cleaning-products

In his interviews, SA talks about the time and cost axis and cleanbiotix is the fourth pillar on that axis because of the number of regulatory hurdles to cross. That said, Stuart also talks about two separate areas that cleanbiotix is aimed at; "Certain categories of Healthcare acquired infections" which clearly require major regulation and hence will be some way away from being ready, but also to "reintroduce good bacteria into the domestic environment", which will I suspect will not require the same level of regulation and hence could possibly be an ingredient in the Croda launch. Be a nice surprise if it was.

Perhaps you need to consider the daily cost of NHS intensive care is £1328 and in the USA a lot more so each day saved through an effective treatment needs to be offset against the cost of that treatment.

https://www.marketwatch.com/story/breaking-down-this-miracle-covid-19-survivors-11-million-hospital-bill-2020-06-16

Need this treatment approved asap

A "major incident" has been declared by the mayor of London as Covid-19 cases continue to spread across the capital.
https://www.bbc.co.uk/news/uk-england-london-55588163

The question is why would now want to extend the warrants, as you rightly point out, they can be exercised at a huge discount whilst any new placing could now be offered on much less of a so discount. Don't lose sight of the fact that the more warrants exercised the more money is made available to accelerate drilling projects and potentially the quicker a big discovery is made that will render the current dilution immaterial.

85,984,200 warrants with a 1p value and expiry date of 18 Feb 2021 now exercised leaving 151,243,658 warrants of 1p that have to be exercised by next month else they lapse.

highrisk, I suspect PJ will exploit the warrant route first if and when required. Providing the sp stays above 3p for 5 consecutive days then there is over £1.5M worth of o/s warrants from the July fundraise alone which PJ can trigger unilaterally.
"Each Subscription Share will have an attaching warrant with an exercise period of two years from admission of the Subscription Shares and exercisable at 0.75p per new ordinary share of 0.1 pence each in the Company ("Ordinary Share"), creating 210,526,316 new warrants (the "Financing Warrants") which are subject to an acceleration clause whereby should the Company's volume weighted average share price exceed 3.00p for 5 consecutive trading days, the Company may at any time write to warrant holders providing 10 working days' notice of accelerated exercise, with 10 working days thereafter for payment"

highrisk, suggest you read the Q&A RNS dated 01st Dec
It's difficult to be precise on future working capital sources but we do have some degree of expectation subject of course to market conditions and buoyancy in the junior resource sector.
Power Metal could undertake financings and the Board are confident that money could be raised as required. This has been amply demonstrated by the £2.7m raised in financings since February 2019 and, save for the initial restructuring in February 2019, Power Metal financings in December 2019 and July 2020 were conducted at the then market price.
Discounted financings are not what Power Metal seeks to undertake as that we consider that potentially damaging for shareholder value and confidence in general.
Ideally, we are seeking to build our working capital to become financially self-sustaining. This would mean that we would not need to undertake financings unless we chose to do so on strong terms or to value-adding institutional investors.
Warrant exercises have provided a considerable amount of additional working capital. The amount raised through warrant exercises since August 2020 has enabled the company to be aggressive with its exploration and corporate plans. In essence each warrant exercise provides us with funds to accelerate our operational activities.
Alongside the above we have a strategic investment portfolio that is growing in value and should that continue, it would provide a source of further working capital should this be needed for operations.
The area where we feel considerable working capital could be generated is from spinouts or other similar commercial transactions where we exchange some of our direct ownership of an interest for mainly cash or shares in other entities.
If those entities are liquid listed vehicles, then the effect is to have an asset easily translatable into cash when and if needed to fund our own operations.

All warrant details below:

Date Warrant Details Option Share Quantity Option Price Trigger Price Expiry Date
28/01/19 Refinancing Business £1M 200000000 1 18/02/21
Mr Brian Moritz, a former non-executive director 6000000 0.5 18/02/21
Andrew Bell options 13613929 1 >1.5 for 5 conseq days 15/02/22
Paul Johnson options 13613929 1 >1.5 for 5 conseq days 15/02/22
SI Capital Limited  2500000 1 18/02/21
SP Angel Limited 2500000 1 18/02/21
10/12/19 Equity Placing and Subscription £700000 175000000 0.7 >2.25 for 10 conseq days POW can trigger 10/12/21
19/02/20 Director Appt Ed Shaw Options 5000000 1 >1.5 for 5 conseq days + 12 mths service 19/02/23
06/07/20 Financing Raise £1M 210526316 0.75 >3 for 5 conseq days Power trigger payment 06/07/22
30/07/20 Andrew Bell options 7500000 2 2 or > for at least 6 months 30/07/23
Paul Johnson options 12500000 2 2 or > for at least 6 months 30/07/23
14/09/20 Canadian Silver Option 9000000 1.75 14/09/23
21/09/20 Kavango Joint Venture 5000000 2 If exercised within 12 mths 5p replacement if sp >7.5 for 5 conseq days pow can trigger purchase 21/09/22
SUM 662754174

Stout, I have built and am maintaining a spreadsheet compiled by going through all the RNS's since the initial fundraise when PJ took charge, and updated each time a warrants RNS is published.

woolworth, the new staff have been brought in because having put the commercial foundation in place in 2020 for the first generation products, reducing administration costs in the process, and with contracts and revenues now growing exponentially, the focus for 2021 is on launching the next generation products and new skill sets are required for this task. It is called growing the business and marks what could be a very exciting year especially now that the commercial partner has been signed up for sweetbiotix.

Total warrants now exercised = 176,893,600 realising £1,453,936.00 for Pow.
The 0.75p warrants are part of the £1M July 20 fundraise and do not have to be exercised until 06th July 2022; so far of the 210,526,316 warrants at 0.75 available 9,500,000 have been exercised early.

Woolworth, the upcoming results for year end Dec 2020 will not be impacted either favourably or unfavourably by the recent director appointments that take place from Jan 2021 and therefore fall into 2021 FY.
"Chris will replace Peter Wennstrom as a director of the Company on confirmation of his appointment. Peter will continue in an advisory capacity for the Company following his resignation from the Board. Chris joined the Board as a Non-Executive Director on 1 January 2021.
October's RNS "Aneta will join the Company on 1 January 2021 and will work towards ensuring timely deliveries of high-quality ingredients to OptiBiotix's partners around the world. Moreover, Aneta is tasked with attaining a BRC certification for OptiBiotix Ltd."